87 related articles for article (PubMed ID: 18444132)
1. Optimal methionine-free diet duration for nitrourea treatment: a Phase I clinical trial.
Durando X; Thivat E; Farges MC; Cellarier E; D'Incan M; Demidem A; Vasson MP; Barthomeuf C; Chollet P
Nutr Cancer; 2008; 60(1):23-30. PubMed ID: 18444132
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of the association of a methionine-free diet with cystemustine therapy in melanoma and glioma.
Thivat E; Farges MC; Bacin F; D'Incan M; Mouret-Reynier MA; Cellarier E; Madelmont JC; Vasson MP; Chollet P; Durando X
Anticancer Res; 2009 Dec; 29(12):5235-40. PubMed ID: 20044642
[TBL] [Abstract][Full Text] [Related]
3. A methionine-free diet associated with nitrosourea treatment down-regulates methylguanine-DNA methyl transferase activity in patients with metastatic cancer.
Thivat E; Durando X; Demidem A; Farges MC; Rapp M; Cellarier E; Guenin S; D'Incan M; Vasson MP; Chollet P
Anticancer Res; 2007; 27(4C):2779-83. PubMed ID: 17695447
[TBL] [Abstract][Full Text] [Related]
4. Dietary methionine restriction with FOLFOX regimen as first line therapy of metastatic colorectal cancer: a feasibility study.
Durando X; Farges MC; Buc E; Abrial C; Petorin-Lesens C; Gillet B; Vasson MP; Pezet D; Chollet P; Thivat E
Oncology; 2010; 78(3-4):205-9. PubMed ID: 20424491
[TBL] [Abstract][Full Text] [Related]
5. Clinical Studies of Methionine-Restricted Diets for Cancer Patients.
Hoffman RM
Methods Mol Biol; 2019; 1866():95-105. PubMed ID: 30725411
[TBL] [Abstract][Full Text] [Related]
6. Nutrient intake and nutritional indexes in adults with metastatic cancer on a phase I clinical trial of dietary methionine restriction.
Epner DE; Morrow S; Wilcox M; Houghton JL
Nutr Cancer; 2002; 42(2):158-66. PubMed ID: 12416254
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of cystemustine, a new cysteamine (2-chloroethyl) nitrosourea: an intrapatient escalation scheme.
Mathé G; Misset JL; Triana BK; Godenèche D; Madelmont JC; Meyniel G
Drugs Exp Clin Res; 1992; 18(4):155-8. PubMed ID: 1451646
[TBL] [Abstract][Full Text] [Related]
8. [Methionine dependency of cancer cells: a new therapeutic approach?].
Durando X; Thivat E; Gimbergues P; Cellarier E; Abrial C; Dib M; Tacca O; Chollet P
Bull Cancer; 2008 Jan; 95(1):69-76. PubMed ID: 18230572
[TBL] [Abstract][Full Text] [Related]
9. Combined methionine deprivation and chloroethylnitrosourea have time-dependent therapeutic synergy on melanoma tumors that NMR spectroscopy-based metabolomics explains by methionine and phospholipid metabolism reprogramming.
Guénin S; Morvan D; Thivat E; Stepien G; Demidem A
Nutr Cancer; 2009; 61(4):518-29. PubMed ID: 19838924
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of mustoforan in management of malignant glioma].
Kobiakov GL
Vopr Onkol; 2007; 53(6):724-9. PubMed ID: 18416147
[No Abstract] [Full Text] [Related]
11. Cystemustine in recurrent high grade glioma.
Durando X; Thivat E; Roché H; Bay JO; Lemaire JJ; Verrelle P; Chazal J; Curé H; Chollet P
J Neurooncol; 2006 Aug; 79(1):33-7. PubMed ID: 16575534
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group.
Cure H; Souteyrand P; Ouabdesselam R; Roche H; Ravaud A; D'incan M; Viens P; Fargeot P; Lentz MA; Fumoleau P; Hanauske A; Chollet P
Melanoma Res; 1999 Dec; 9(6):607-10. PubMed ID: 10661773
[TBL] [Abstract][Full Text] [Related]
13. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study.
Beauchesne PD; Taillandier L; Bernier V; Carnin C
Cancer Chemother Pharmacol; 2009 Jun; 64(1):171-5. PubMed ID: 19352662
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
Yen Y; Lim DW; Chung V; Morgan RJ; Leong LA; Shibata SI; Wagman LD; Marx H; Chu PG; Longmate JA; Lenz HJ; Ramanathan RK; Belani CP; Gandara DR
Am J Clin Oncol; 2008 Aug; 31(4):317-22. PubMed ID: 18845988
[TBL] [Abstract][Full Text] [Related]
15. Second-line chemotherapy of disseminated malignant melanoma with cystemustine at 60 mg/m2: a phase II trial.
Thivat E; Durando X; D'Incan M; Cure H; Mouret-Reynier MA; Madelmont JC; Souteyrand P; Chollet P
Anticancer Drugs; 2005 Oct; 16(9):1003-7. PubMed ID: 16162977
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
17. Treatment of malignant gliomas with surgery, intra-arterial infusions of 1-(2-hydroxyethyl)chloroethylnitrosourea, and radiation therapy: a phase II study.
Fauchon F; Davila L; Chatellier G; Fohanno D; Philippon J; Rey A; Chiras J; Poisson M; Delattre JY
Neurosurgery; 1990 Aug; 27(2):231-4. PubMed ID: 2385341
[TBL] [Abstract][Full Text] [Related]
18. Effect of increased methionine level on performance and apparent ileal digestibility of amino acids in ducks.
Jamroz D; Wiliczkiewicz A; Lemme A; Orda J; Skorupińska J; Wertelecki T
J Anim Physiol Anim Nutr (Berl); 2009 Oct; 93(5):622-30. PubMed ID: 18700850
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of cystemustine in metastatic colorectal carcinoma. A trial of the EORTC Clinical Screening Group.
Kerbrat P; Adenis A; Rebattu P; Roche H; Chevallier B; Chollet P; Krakowski I; Lentz MA; Fumoleau P
Eur J Cancer; 1993; 29A(11):1597-9. PubMed ID: 8217367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
